Sep 12, 2024 ProMIS Neurosciences to Showcase PMN310’s Ability to Target Toxic Oligomers and Distinguish from Other Amyloid-Beta Oligomers in Preclinical Studies at the 4th International Conference on Cognitive & Behavioral Neurosciences
Sep 5, 2024 ProMIS Neurosciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Aug 8, 2024 ProMIS Neurosciences Announces Second Quarter 2024 Financial Results and Recent Highlights
Aug 6, 2024 ProMIS Neurosciences Announces Data on the Pathogenic Role of Toxic Misfolded SOD1 Aggregates in ALS Published in Acta Neuropathologica and Open Biology
Jul 30, 2024 ProMIS Neurosciences Showcases Novel Vaccine Approach for Maximal Targeting of Toxic Amyloid-Beta Oligomers at the 2024 Alzheimer’s Association International Conference
May 14, 2024 ProMIS Neurosciences Announces First Quarter 2024 Financial Results and Recent Highlights
Apr 30, 2024 ProMIS Neurosciences Publishes Study Highlighting Oligomer Selectivity and Benefit of Amyloid-Beta-Directed Antibodies